Targepeutics is focused on developing innovative treatments for aggressive brain cancers, specifically targeting glioblastoma (GBM) and diffuse midline glioma (DMG). Their lead candidate, GB-13, is a novel biologic therapy that has received orphan drug designation from the FDA, which facilitates access to essential resources for its development. GB-13 is designed to specifically target the cancer-associated IL13Rα2 receptor, which is prevalent in these types of tumors. This targeted approach aims to induce cancer cell death while being integrated into existing treatment regimens, addressing a significant unmet need in the oncology landscape where no new therapies have been approved for these cancers in over two decades.

The company emphasizes a commitment to drug discovery and development that prioritizes safety and efficacy. By leveraging their platform, Targepeutics aims to create highly selective therapies that can deliver meaningful results for patients suffering from GBM and DMG. Their clinical design strategy is centered on bringing GB-13 to clinical trials, with the goal of improving survival rates and quality of life for patients and their families. Targepeutics is driven by a personal mission to enhance treatment options for brain cancer, reflecting a deep understanding of the challenges faced by patients and their loved ones.

United States

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight and diagnose cancer and other diseases.  Our lead compound, GB-13, is currently advancing toward a Phase I clinical trial for several cancer targets.  GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.  We have also licensed related technology for a cancer immunotherapy that is in Phase III clinical trials.

Targepeutics

Company Details